HOUSTON, Dec. 6, 2018 /PRNewswire/ -- Marker Therapeutics,
Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company, today
announced that its President and CEO, Peter
L. Hoang, will present a corporate overview at the upcoming
Tumor Targeted Lymphocytes Summit on Wednesday, December 12, 2018.
Presentation Details:
Title: A Novel Therapy That Targets Multiple Tumor
Antigens Using Non-Genetically Modified T Cells Can Drive Powerful
Anti-Tumor Response
Date: Wednesday, December 12,
2018
Time: 12:30pm EST
Location: Hilton Boston Back Bay, Boston, MA
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology
company specializing in the development of next-generation T
cell-based immunotherapies for the treatment of hematological
malignancies and solid tumor indications. Marker's cell therapy
technology is based on the selective expansion of non-engineered,
tumor-specific T cells that recognize tumor associated antigens
(i.e. tumor targets) and kill tumor cells expressing those targets.
Once infused into patients, this population of T cells attacks
multiple tumor targets and acts to activate the patient's immune
system to produce broad spectrum anti-tumor activity. Because
Marker does not genetically engineer its T cells, when compared to
current engineered CAR-T and TCR-based approaches, its products (i)
are significantly less expensive and easier to manufacture, (ii)
appear to be markedly less toxic, and (iii) are associated with
meaningful clinical benefit. As a result, Marker believes its
portfolio of T cell therapies has a compelling therapeutic product
profile, as compared to current gene-modified CAR-T and TCR-based
therapies.
Marker is also advancing a number of innovative peptide- and
gene-based immuno-therapeutics for the treatment of cancer and
metastatic disease, including our Folate Receptor Alpha program
(TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide
antigen program (TPIV100/110) in Phase II clinical trials. In
parallel, we are developing a proprietary DNA expression technology
named PolyStart™ to improve the ability of the cellular immune
system to recognize and destroy diseased cells.
For additional information, please call toll free at (904)
862-6490 or visit: markertherapeutics.com
To receive future press releases via email, please visit:
https://markertherapeutics.com/email-alerts/
Follow us on Twitter @MRKRTherapeutic, or follow us on
Facebook.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements in this news release concerning the Company's
expectations, plans, business outlook or future performance, and
any other statements concerning assumptions made or expectations as
to any future events, conditions, performance or other matters, are
"forward-looking statements". Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
our research and development activities relating to our multi-tumor
antigen specific T cell therapies; our TPIV200 and TPIV100/110
programs and our PolyStart™ program; the effectiveness of these
programs or the possible range of application and potential
curative effects and safety in the treatment of diseases; and, the
timing and success of our clinical trials. Forward-looking
statements are by their nature subject to risks, uncertainties and
other factors which could cause actual results to differ materially
from those stored in such statements. Such risks, uncertainties and
factors include, but are not limited to the risks set forth in the
Company's most recent Form 10-K, 10-Q and other SEC filings which
are available through EDGAR at www.sec.gov. The Company assumes no
obligation to update the forward-looking statements.
statements.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-the-tumor-targeted-lymphocytes-summit-300760899.html
SOURCE Marker Therapeutics, Inc.